A team of scientists led by Scott Abrams at Roswell Park Comprehensive Cancer Center uncovered a pathway associated with metastases to the lung, a common site for cancer spread. The work, just published in JCI Insight, has potentially significant implications that may point to novel cancer therapies.
Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.
